Final answer:
The FDA issued a Public Health Advisory in 2000 regarding the safety of phenylpropanolamine (PPA), due to the risk of stroke in younger women, leading to its restricted availability in the U.S. This falls under health concerns monitored by the FDA, which includes the monitoring of other chemicals like BPA.
Step-by-step explanation:
In November 2000, the FDA issued a Public Health Advisory regarding the safety of phenylpropanolamine (PPA). This advisory was based on a study showing a proposed increased risk of stroke, particularly in younger women. Consequently, in the United States, PPA was no longer sold without a prescription. However, in some countries in Europe, PPA is still available, either by prescription or over-the-counter. The Food and Drug Administration Amendments Act (FDAAA) of 2007 further enforced the need for ongoing postmarking safety assessments of pharmaceuticals, like PPA, to ensure long-term safety and effective risk management.
After a drug receives initial marketing approval, it must be subjected to rigorous pharmacovigilance to monitor its effects on various patient subgroups and to assess any long-term health risks that may arise. While the FDA and other organizations such as the EPA and CDC continue to monitor and regulate chemicals and drugs, some substances like BPA have come under scrutiny and have seen a decreased use in food-related materials due to potential endocrine-disrupting effects.